RealTime Dynamix™: Psoriasis US Q3 2017 Spotlight

Over the past two years, four new biologics and multiple biosimilars have been approved for the treatment of Psoriasis in the US, and dermatologists are feeling increasingly overwhelmed with the sheer number of new entrants, according to RealTime Dynamix™ Psoriasis US Q3.

Click the button below to view highlights from this report:

Download Report Spotlight

Early launch metrics for Janssen’s Tremfya may lag those of Lilly’s Taltz at a similar post-launch bperiod, but signs indicate the new IL-23 inhibitor is poised for significant growth mostly at the detriment to Janssen’s own Stelara according to RealTime Dynamix™: Psoriasis US Q3 (n=98).

Click the button below to view highlights from this report:

Download Report Spotlight II

2017-10-17T19:41:05+00:00